Testosterone Cypionate Injectable Recalled for Manufacturing Quality Issues
Sun Pharmaceutical recalls 97,450 vials of Testosterone Cypionate Injection nationwide due to manufacturing deviations that could cause out-of-specification impurities.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II classification for a prescription medication with confirmed manufacturing deviations that could affect product specification and purity. No illnesses or injuries have been reported, limiting the maximum score to 3 per the rubric.
Plain-English summary
Testosterone Cypionate Injection, USP 200 mg/mL, manufactured by Sun Pharmaceutical Industries Inc and distributed nationwide in the USA and Puerto Rico, is being recalled. The product is sold under NDC 62756-015-40, 62756-017-40, and 62756-016-40, with lot codes HAC1974A and HAC1978A and expiration date 06/2023.
The recall was initiated due to manufacturing deviations. Some lots of Testosterone Cypionate were previously rejected due to manufacturing issues that could cause the product to be out of specification for impurities. Lots made with the same active pharmaceutical ingredient are being recalled as a precaution, as they could potentially be affected by similar manufacturing deviations.
Approximately 97,450 vials are affected by this recall. The product is a prescription injectable used for testosterone replacement therapy.
Patients currently using this medication should consult their healthcare provider or pharmacist to determine if they have affected product. Healthcare providers and patients should not discontinue testosterone replacement therapy without medical guidance.
The recalled product
- Product
- TESTOSTERONE CYPIONATE (TESTOSTERONE CYPIONATE)
- Brand
- TESTOSTERONE CYPIONATE
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Category
- Drug
- Affected units
- 97,450
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- HAC1974A
- HAC1978A
- Exp 06/2023
UPCs (3)
- 0362756017405
- 0362756015401
- 0362756016408
Distribution
Related recalls
Same brand · TESTOSTERONE CYPIONATE
- ModerateTestosterone Cypionate Injection Recalled for Insoluble Crystals
FDA (Drugs) · 2025-04-23
- HighTestosterone Cypionate Injection Recalled for Manufacturing Defect
FDA (Drugs) · 2023-04-12
- HighTestosterone Cypionate Injection Recalled for Water Leakage in Manufacturing
FDA (Drugs) · 2022-07-20
- ModerateTestosterone Cypionate Injectable Drug Recalled for Manufacturing Deviations
FDA (Drugs) · 2022-07-13
- HighTestosterone Cypionate Injectable Recalled Due to Manufacturing Sterility Deviation
FDA (Drugs) · 2022-06-29
Same manufacturer · SUN PHARMACEUTICAL INDUSTRIES INC
See all →- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08
- HighPerampanel Prescription Tablets Recalled for Labeling Mix-up
FDA (Drugs) · 2026-07-01
- HighBudesonide inhalation ampules contain black and brown specks and particles
FDA (Drugs) · 2026-06-17
- SevereDoxorubicin liposome injection vials contain glass particulate matter
FDA (Drugs) · 2026-06-17
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17